Publications Template

#	Research Title	Field	Abstract	Year of Publication Publishing	Publishing Link "URL"
1	**Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/ STAT-3/ SOCS-3 pathway**	Pharmacology and Toxicology	The phytochemical sulforaphane (SFN) has been studied for its potential anti-obesity effect, but neither its molecular targets nor its interaction with the antimalarial drug chloroquine (CQ) has been fully delineated. Therefore, high-fat diet (HFD) obese rats were randomly allocated into one of five groups and were left untreated or gavaged orally with SFN (0.5 or 1 mg/kg), CQ (5 mg/kg), or their combination (0.5/5 mg/kg) for six successive weeks to assess their potential interaction and the enrolled mechanisms. SFN effectively reduced the HFD-induced weight gain, blood glucose, and serum	2022	https://www.scopus.com/record/display.uri?eid=2-s2.0-85131557108&origin=resultslist&sort=plf-f&src=s&sid=4378001eb0e69f1e6271d2a878a1b0b4&sot=b&sdt=b&s=TITLE-ABS-KEY%28Chloroquine+modulates+the+sulforaphane+anti-obesity+mechanisms+in+a+high-fat+diet+model%3A+Role+of+JAK-2%2F+STAT-3%2F+SOCS-3+pathway%29&sl=141&sessionSearchId=4378001eb0e69f1e6271d2a878a1b0b4

			leptin levels, and improved lipid profile.		
2	**A Study of a New Therapeutic Protocol Concerning the Pre-treatment of Two Different Breast Cancer Cell Lines by 5-Aza-2′-deoxycytidine**	Pharmacology and Toxicology	Breast cancer is the second most common cancer in the world and the most frequent cancer among women. Hormonal therapy is the main stay in the clinical management of patients with ER+ breast cancer. However, as cancer progresses, patients become resistant anti-estrogens and most patients no longer respond to endocrine therapy which may highlights the urgent need for new therapeutic protocol other than anti-estrogen therapeutic regimen. The aim of the current study is to determine and evaluate the impact of re- expressing estrogen receptor beta through the demethylating agent 5-aza-2′-deoxycytidine (Decitabine) pre-treatment on two different breast cancer cell lines MCF-7 (4OHT sensitive) and	-	In progress

			LCC-2 (4OHT resistant) in the presence or absence of either tamoxifen or raloxifene. In order to determine the possible anti-tumor effects of these drugs, the level of expression and the activity of the following parameters; ERα, ER-β, caspase-3, β-catenin, cyclin-D1, human epidermal growth factor receptor 2 (HER-2) and insulin-like growth factor (IGF)-1 were determined.		
3					